Article Text

Download PDFPDF
Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor α treatment
  1. K Briot1,
  2. P Garnero2,
  3. A Le Henanff1,
  4. M Dougados1,
  5. C Roux1
  1. 1Rheumatology Department, Cochin Hospital, René Descartes University, Paris, France
  2. 2INSERM Research Unit 403 and Molecular Markers, SYNARC Lyon, France
  1. Correspondence to:
    Professor C Roux
    Hôpital Cochin, Département de Rhumatologie, 27 rue du Faubourg St Jacques, 75014 Paris, France;


Objectives: To determine the changes in body weight, body composition, and bone turnover in patients with spondyloarthropathy (SpA) treated with anti-tumour necrosis factor α (TNFα).

Patients and methods: 19 patients with SpA (2 women, 17 men), aged 21–71 years, were studied in a 1 year prospective open study. 17 patients received infliximab: 3 or 5 mg/kg/infusion at weeks 0, 2, 6 and infusions in the case of a relapse (n = 14) or systematically (n = 3); 2 patients received etanercept (25 mg twice a week). Body weight, body composition (lean mass, fat mass), and bone mineral density (BMD; using dual energy x ray absorptiometry) were measured at baseline and at months 6 and 12. Serum insulin-like growth factor-I (IGF-I), bone markers (carboxy terminal telopeptide of collagen Ι (CTX) and procollagen type Ι N terminal propeptide (PINP)) were measured at baseline and months 3, 6, and 12.

Results: In 1 year there was a significant increase in body weight (mean (SD) 2.24 (3.1) kg, p = 0.0004), and in lean mass (1.4 (1.69) kg, p = 0.005), but no changes in fat mass. BMD increased at the spine (5.6%, p = 0.0005) and total femur (2.6%, p = 0.01). CTX decreased from the third month (−50%, p = 0.005) up to 1 year (−30%, p = 0.012), and a trend for an increase in PINP (10%, p = 0.06) and in IGF-I (15%, p = 0.04) was seen at month 3.

Conclusion: These data confirm that treatment with anti-TNFα in SpA is associated with an increase of BMD, which results from a decrease of bone resorption. Increase in body weight and lean mass is observed in parallel with an increase in IGF-1.

  • BASDAI, Bath Ankylosing Spondylitis Disease Activity Index
  • BASFI, Bath Ankylosing Spondylitis Functional Index
  • BMD, bone mineral density
  • CRP, C reactive protein
  • CTX, carboxy terminal telopeptide of type I collagen
  • DXA, dual energy x ray absorptiometry
  • ESR, erythrocyte sedimentation rate
  • GH, growth hormone
  • IGF-I, insulin-like growth factor-I
  • IL, interleukin
  • PINP, procollagen type I N-terminal propeptide
  • RA, rheumatoid arthritis
  • SpA, spondyloarthropathy
  • TNFα, tumour necrosis factor α
  • anti-tumour necrosis factor
  • spondyloarthropathy
  • osteoporosis
  • body composition
  • bone remodelling

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.